This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: ASCO, Sarepta, Cel-Sci and Hate Mail!

BOSTON ( TheStreet) -- I'm trying to incorporate more actual tweets in the Biotech Stock Mailbag.

Earlier this week, the American Society of Clinical Oncology (ASCO) posted the itinerary planner for its annual meeting. Research abstract titles and presentation times are now available and searchable.

I fear this year's ASCO meeting might be a tad boring from a Wall Street perspective. ASCO is cyclical, with strong and weak years. The upcoming meeting looks to be the latter. With that said, here are some highlights based on my first, quick look through the abstracts:

This year's plenary session features two presentations on Roche's (RHHBY) Avastin, one each in glioblastoma (brain cancer) and cervical cancer. Onyx Pharmaceuticals (ONXX) will also present results from the phase III "Decision" trial of Nexavar in thyroid cancer.

Synta Pharmaceuticals (SNTA): Updated results from the phase II "Galaxy-1" study of ganetespib in non-small cell lung cancer. Abstract No. CRA8007.

Amgen (AMGN): Detailed results from the positive phase III study of T-Vec in melanoma. Abstract No. LBA9008.

Ariad Pharmaceuticals (ARIA): Updated results from the early, proof-of-concept study of AP26113. Abstract No. 8031

Gilead Sciences (GILD) will have several presentation on PI3k inhibitor idealisib. Check out abstract nos. 8519, 7005, 8500 and 8501.

Bristol-Myers Squibb's (BMY) anti PD-1 nivolumab will definitely take a star turn at the ASCO meeting this year. Check out abstract nos. 9011, 9012, CRA9006 and 3002.

Roche also has a PD-L1 antibody, MPDL3280A, in development. Abstract Nos. 4505, 3000 and 8008.

FDA just awarded Merck's (MRK) anti PD-1 lambrolizumab with breakthrough therapy designation. Check out abstract no. 9009.

Oncothyreon (ONTY): The failed Stimuvax lung cancer phase III trial will be presented. Abstract No. 7500.

Array Biopharma (ARRY): Phase II data from the combination study of selumitinib plus dacarbazine in melanoma. Abstract No. 9004

That's a start. The contents of most of the ASCO research abstracts will be posted online May 15 at 6 pm ET. There will be much more to talk about once we get more than just the titles.

Sarepta Therapeutics (SRPT - Get Report) shares are weak due to heightened speculation that FDA will reject the company's request to seek accelerated approval for its Duchenne muscular dystrophy drug eteplirsen. The confidence of the "no accelerated approval" crowd has been bolstered by a series of conference calls sponsored by sell-side analysts over the past week. These calls have featured experts expressing doubts about Sarepta's ability to correlate dystrophin production with the benefit observed by patients on the six-minute walk test.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AMRN $1.80 0.00%
AVEO $0.89 0.00%
CVM $0.59 0.00%
SRPT $17.22 0.00%
SNTA $0.39 0.00%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs